3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
38
Carcinoma, Renal Cell
12
Carcinoma, Non-Small-Cell Lung
12
Squamous Cell Carcinoma of Head and Neck
8
Head and Neck Neoplasms
8
Carcinoma, Merkel Cell
8
Uterine Cervical Neoplasms
7
Stomach Neoplasms
7
Colorectal Neoplasms
6
Carcinoma, Transitional Cell
6
Carcinoma, Hepatocellular
6
Small Cell Lung Carcinoma
5
Neoplasms
5
Kidney Neoplasms
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Esophageal Neoplasms
3
Breast Neoplasms
3
Urogenital Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Neoplasms by Histologic Type
2
Microsatellite Instability
2
Mesothelioma, Malignant
2
Mesothelioma
2
Lymphoma
2
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Squamous Cell
2
Interventions
veliparib
1
tislelizumab
1
spartalizumab
1
erythromycin propionate-N-acetylcysteinate
1
entinostat
1
atezolizumab
1
Transurethral Resection of Prostate
1
Taxes
1
Surveys and Questionnaires
1
Semaxinib
1
Radiosurgery
1
Quality of Life
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Immunotherapy
1
Immunohistochemistry
1
Genetic Profile
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Filgrastim
1
FAPI-46
1
Drug Therapy
1
Docetaxel
1
Cyclophosphamide
1
Cryosurgery
1
Carboplatin
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Unknown Primary
×
atezolizumab
×
Dermatologic
×
Clear all
NCT04273061
2025-09-22
CAPTIV-8
British Columbia Cancer Agency
Phase 2
Recruiting
200 enrolled